FPFitria Febriliani Putri

Fitria Febriliani Putri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fitria Febriliani Putri has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Dio Giovanni Ariel

    Study Program of Pharmacy, Faculty of Medicine, Universitas Brawijaya Malang

    2 shared publications
  • Kana Mardhiyyah

    Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Brawijaya Malang; Department of Biochemistry and Biomolecular, Faculty of Medicine, Universitas Brawijaya Malang; Malaria Research Group, Faculty of Medicine, Universitas Brawijaya Malang

    2 shared publications
  • Loeki Enggar Fitri

    Department of Clinical Parasitology, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, Indonesia

    2 shared publications
  • Rivo Yudhinata Brian Nugraha

    Affiliations Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Clinical Parasitology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia

    2 shared publications
  • Sri Winarsih

    Pharmacy Study Program, Faculty of Medicine, Universitas Brawijaya Malang; Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Brawijaya Malang; Malaria Research Group, Faculty of Medicine, Universitas Brawijaya Malang

    2 shared publications
  • Ajeng Maharani Putri

    Univ Brawijaya, Fac Med, Malaria Res Grp, Malang 65145, East Java, Indonesia

    1 shared publication

Latest Publications

  • Open Access

    Optimation of Combination of N-Hexane Solution and Ethyle Acetate on Secondary Metabolite Compounds Profile of Streptomyces hygroscopicus

    by Dio Giovanni Ariel, Sri Winarsih, Fitria Febriliani Putri, Nabila Erina Erwan, Ajeng Maharani Putri, Alfian Wika Cahyono, Kana Mardhiyyah, Loeki Enggar Fitri, Rivo Yudhinata Brian Nugraha

    Streptomyces hygroscopicus (S.hygroscopicus) is a Gram-positive soil bacterium that can produce secondary metabolites from fermentation that have a therapeutic effect. The fermented S. hygrocospicus metabolites that are still in the form of crude extracts are difficult to develop as drug preparations because the active compounds are not yet known, so it will be challenging to determine the dosage of drugs that have a therapeutic effect. Therefore, it is necessary to carry out exploratory research to narrow down the secondary metabolite profile from the fermentation of S. hygroscopicus, using extraction and fractionation methods, which are then identified by Thin-Layer Chromatography (TLC) using a combination of solvents. This study used the extraction method with a separating funnel. The fractionation was carried out using the BUCHI (Sepacore®) Flash Chromatography and Reveleris® PREP Purification System column chromatography gradually using ethyl acetate and n-hexana. 47 and 60 of the fractionation results were taken as samples, that further were profiled using TLC and given the appearance of 10% KOH stains and p-Anisaldehyde - sulfuric acid, so that various classes of compounds with different Rf values were obtained, namely Monoterpenes, Triterpenes, Steroids, Saponins, Coumarin, Scopoletin, and Alkaloids.


  • Open Access

    Antimalarial Properties of Isoquinoline Derivative from Streptomyces hygroscopicus subsp. Hygroscopicus: An In Silico Approach

    by Rivo Yb. Nugraha, Icha Fd. Faratisha, Kana Mardhiyyah, Dio G. Ariel, Fitria F. Putri, Nafisatuzzamrudah, Sri Winarsih, Teguh W. Sardjono, Loeki E. Fitri

    Malaria is one of the life‐threatening diseases in the world. The spread of resistance to antimalarial drugs is a major challenge, and resistance to artemisinin has been reported in the Southeast Asian region. In the previous study, the active compound of Streptomyces hygroscopicus subsp. Hygroscopicus (S. hygroscopicus), eponemycin, has been shown to have antimalarial effects. To further analyze the effects of other active compounds on the Plasmodium parasite, identifying and analyzing the effectiveness of compounds contained in S. hygroscopicus through instrumentation of liquid chromatography/mass spectrometry (LC/MS) and in silico studies were very useful. This study aimed at identifying other derivative compounds from S. hygroscopicus and screening the antimalarial activity of the compound by assessing the binding affinity, pharmacokinetic profile, and bond interaction. The derivative compounds were identified using LC/MS. Protein targets for derivative compounds were found through literature studies, and the results of identification of compounds and protein targets were reconstructed into three‐dimensional models. Prediction of pharmacokinetic profiles was carried out using Swiss ADME. Screening of protein targets for the derivative compound was carried out using the reverse molecular docking method. Analyzing bond interaction was done by LigPlot. One compound from S. hygroscopicus, i.e., 6,7‐dinitro‐2‐[1, 2, 4]triazole‐4‐yl‐benzo[de]isoquinoline‐1,3‐dione, was successfully identified using LC/MS. This compound was an isoquinoline derivative compound. Through literature studies with inclusion criteria, thirteen protein targets were obtained for reverse molecular docking. This isoquinoline derivative had the potential to bind to each protein target. The pharmacokinetic profile showed that this compound had the drug‐likeness criteria. Conclusion. 6,7‐Dinitro‐2‐[1, 2, 4]triazole‐4‐yl‐benzo[de]isoquinoline‐1,3‐dione has antimalarial activity as shown by reverse molecular docking studies and pharmacokinetic profiles. The best inhibitory ability of compounds based on bond affinity is with adenylosuccinate synthetase.